Functional SARS-CoV-2-specific immune memory persists after mild COVID-19.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
13 Aug 2020
13 Aug 2020
Historique:
entrez:
21
8
2020
pubmed:
21
8
2020
medline:
21
8
2020
Statut:
epublish
Résumé
The recently emerged SARS-CoV-2 virus is currently causing a global pandemic and cases continue to rise. The majority of infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that might contribute to herd immunity. Thus, we performed a longitudinal assessment of individuals recovered from mildly symptomatic COVID-19 to determine if they develop and sustain immunological memory against the virus. We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset. Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-γ and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies. These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.
Identifiants
pubmed: 32818218
doi: 10.21203/rs.3.rs-57112/v1
pmc: PMC7430600
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : T32 AI106677
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR002318
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Sci Transl Med. 2013 Mar 13;5(176):176ra32
pubmed: 23486778
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Cell Rep. 2019 Apr 30;27(5):1446-1460.e4
pubmed: 31042472
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Nat Immunol. 2013 Apr;14(4):372-9
pubmed: 23475182
JCI Insight. 2017 Apr 20;2(8):
pubmed: 28422752
Nat Immunol. 2011 Jun;12(6):467-71
pubmed: 21739668
Emerg Infect Dis. 2007 Oct;13(10):1562-4
pubmed: 18258008
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
J Immunol. 2020 Aug 15;205(4):915-922
pubmed: 32591393
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Immunol. 2011 Jun 15;186(12):7264-8
pubmed: 21576510
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5545-50
pubmed: 11960012
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Ann N Y Acad Sci. 1996 Oct 25;797:166-76
pubmed: 8993360
Immunity. 2009 Jan 16;30(1):92-107
pubmed: 19119024
Annu Rev Immunol. 2017 Apr 26;35:255-284
pubmed: 28142324
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):E3216-24
pubmed: 23922396
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Annu Rev Immunol. 2016 May 20;34:335-68
pubmed: 26907215
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Cell Mol Immunol. 2020 Jul;17(7):773-775
pubmed: 32467617
PLoS One. 2017 Oct 24;12(10):e0186998
pubmed: 29065175
Immunity. 2016 Aug 16;45(2):402-14
pubmed: 27473412
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Cell Immunol. 2017 Nov;321:26-34
pubmed: 28739077
Front Immunol. 2018 Apr 09;9:678
pubmed: 29686673
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Nat Commun. 2020 Sep 4;11(1):4420
pubmed: 32887876
Immunol Rev. 2019 Mar;288(1):149-160
pubmed: 30874358
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Cell Rep Med. 2021 Jan 19;2(1):100189
pubmed: 33495758
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Annu Rev Immunol. 2020 Apr 26;38:705-725
pubmed: 32340571